The award of the grant is a real success for the Radboud Expert Centre for Mycobacterial Disease that was recently recognized by the NFU, the Netherlands Federation of UMCs within the theme of Infectious diseases and global health within the RIHS.
The PanACEA consortium is a drug development program that started in 2009 with a grant of 27 million Euro for phase II and III clinical trials to optimize tuberculosis treatment, more specifically for the further evaluation of high dose rifampicin, a new compound SQ109 and moxifloxacin. The program is coordinated by Martin Boeree from the Department of Lung Diseases (photo left) with Rob Aarnoutse from the Department of Pharmacy (photo below) as pharmacological expert. PanACEA is a consortium with collaboration between 11 African institutes and 6 Universities from Europe.
PanACEA has now attained a new grant of 15 million to continue its work from 2016-2021. This grant was obtained from the European & Developing Countries Clinical Trials Partnership EDCTP which is a part of Horizon 2020. The program concentrates on identification of the maximum tolerated dose of rifampicin, the optimization of the “old” drug pyrazinamide and the evaluation of two new compounds Q203 and BTZ043.
In three phase IIa trials and one pivotal large so-called phase IIc trial the consortium is aiming to contribute to the final goal of considerably shortening TB treatment for better compliance and prevention of the emergence of resistance. This is in line with the End TB strategy from the WHO, aiming at the pre elimination of TB in 2050. Presently, every year nine million people get tuberculosis and more than one million die from the disease. The combination with HIV and the development of multidrug resistant forms of tuberculosis makes the fight against the disease a real challenge.
<< back to overview news items